Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC study.

Date publication

septembre 2025

Journal

Lung cancer (Amsterdam, Netherlands)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GALLAND Loïck

Tous les auteurs :
Pierret T, Greillier L, Guisier F, Daniel C, Descourt R, Galland L, Molinier O, Decroisette C, Cortot A, Moreau D, Gamé LB, Wislez M, Cloarec N, Curcio H, Delberghe N, Cadranel J, Duchemann B, Toffart AC, Chouaïd C, Auliac JB

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41039676

Résumé

Amivantamab is a bispecific anti-EGFR-MET antibody approved to treat non-small cell lung cancers (NSCLCs) harbouring EGFR exon 20 insertions (EGFR-exon20ins).

Mots clés

Amivantamab, Bispecific antibody, Epidermal growth factor receptor exon-20, Non-small cell lung cancers Targeted therapy

Référence

Lung Cancer. 2025 09 26;209:108766